Erasca
Erasca is a biotechnology company based in San Diego, California, dedicated to eradicating cancer by comprehensively targeting the RAS/MAPK pathway, implicated in millions of new cancer cases annually.
Company Overview
Erasca is a biopharmaceutical company headquartered in San Diego, California, focused on eradicating cancer. Their approach targets the RAS/MAPK pathway, which is implicated in approximately 5.5 million new cancer cases globally each year. Erasca is developing a modality-agnostic portfolio of therapeutic programs designed to comprehensively shut down this pathway.
Research and Development
Erasca is dedicated to developing innovative therapeutic solutions targeting the RAS/MAPK pathway. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the company presented three research studies, highlighting advances in their ongoing projects. Their scientific efforts aim to address a significant portion of global cancer cases by inhibiting this critical pathway.
Financing and Investment
In March 2024, Erasca announced a $45 million oversubscribed private placement financing. This financial boost is set to enhance their research and development activities, further supporting their mission to eradicate cancer. The financing reflects strong investor confidence in Erasca's strategic approach and potential impact.
The Erasca Foundation
Established in May 2021, the Erasca Foundation was created to support cancer research and patient advocacy. The foundation is funded by the donation of 1% of Erasca's capital stock at the time of their Initial Public Offering (IPO). This initiative underscores Erasca's commitment to making a broader, positive impact in the fight against cancer.